BUHLMANN News

IBDoc is Now Part of the TactioRPM

image credit: newswire.com US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Tactio Health Group and Telia Company team up to accelerate the development of patient-centred digital health programs in Sweden and other Nordic and Baltic countries. The Swedish telecommunication company Telia, together with AbbVie Sweden, developed the
Continue Reading

Join Us at AMLI 2018

We offer a comprehensive autoimmunity product line comprised of robust assays for simple, esoteric testing for important markers and it is supported by numerous publications.  Anti-MAG Autoantibodies ELISA  This assay is intended for the quantitative determination of human IgM-auto-antibodies directed against Myelin Associated Glycoprotein (MAG) in serum. Health Canada License: 89118 US: Research Use Only.  Not
Continue Reading

Visit BUHLMANN at PNS 2018

We offer a comprehensive neuroimmunology product line comprised of robust assays for simple, esoteric testing for important neuroimmune markers and it is supported by numerous publications.   BÜHLMANN GanglioCombi® MAG ELISA - intended to detect autoantibodies against defined relevant neural antigens/epitopes in human serum samples. Health Canada License: 100476 US: Research Use Only. Not for diagnostic
Continue Reading

Join BUHLMANN at AACC 2018

BÜHLMANN fCAL® ELISA, accurate, precise, efficient calprotectin testing Health Canada License: 80726 US:  BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use. Quantum Blue® platform offering rapid and quantitative results for fecal calprotectin, serum calprotectin, CRP, serum infliximab trough levels, and serum adalimumab trough levels (Additional trough level assays coming soon!) Health Canada Licenses: Quantum Blue®  fCAL: 83477, Quantum Blue® fCAL extended: 100161 US: Research Use Only. Not
Continue Reading

BÜHLMANN Laboratories AG Receives FDA Clearance for its fCAL® ELISA Calprotectin Test

BÜHLMANN fCAL® ELISA, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. Amherst NH, June 12, 2018: BÜHLMANN Laboratories AG, is proud to announce it has received United States Food and
Continue Reading

BUHLMANN – LabSense News Spring 2018 Edition

In this “Summer Edition” we are pleased to share the launch of the of Quantum Blue® Adalimumab assay as well as announce some recent enhancements to the Quantum Blue® Infliximab assay. We also make mention of the upcoming meetings…

Continue Reading

IBDoc and Me

Health Canada Licence: 98903, Device class: 3  IBDoc® is not available for sale in the US. Read perspectives and insights from a patient from the UK who has been using IBDoc®  since last October and is trying this new tool to monitor his Crohn’s Disease.  He has been documenting his experiences in a blog to share his
Continue Reading

From BÜHLMANN Quantum Blue® to fCAL turbo® Follow the Evolution of Calprotectin Testing at James Cook University Hospital

Mr. Andrew Teggert, Clinical Scientist, James Cook University Hospital with SIEMENS ADVIA Chemistry XPT BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 An interview with Mr. Andrew Teggert, Clinical Scientist, James Cook University Hospital, Middlesbrough. At the largest hospital in Tees Valley,
Continue Reading

The New Biosimilar of Infliximab SB2 Can be Quantified by IFX-Optimized Therapeutic Drug Monitoring Assays

BÜHLMANN Quantum Blue® Infliximab Citation: Magro, F., Rocha, C. et al. P229 The new biosimilar of infliximab SB2 can be quantified by IFX-optimized therapeutic drug monitoring assays.  Journal of Crohns and Colitis.  2018, Jan. DOI: 10.1093/ecco-jcc/jjx180.356. BÜHLMANN Quantum Blue® Infliximab is for Research Use Only in the US.  Not for use in diagnostic procedures in the US. Health Canada License:
Continue Reading

A Pilot Study Using Point of Care Testing for Infliximab and Faecal Calprotectin in IBD Patients

BÜHLMANN Quantum Blue® Infliximab Citation: Sophie Restellini, Talat Bessissow, Carolyne Lemieux, Che-Yung Chao, Gary Wild, Ernest Seidman, Alain Bitton, Peter L. Lakatos, Waqqas Afif.  P711 A pilot study using point of care testing for infliximab and faecal calprotectin in IBD patients with a secondary loss of response.  Journal of Crohn's and Colitis. 2018 Jan. DOI: 10.1093/ecco-jcc/jjx180.838. Highlight from this
Continue Reading